Skip to main content
Back to feed
HealthReportedMedium
5.2

FDA delays decision on Novo's hemophilia A drug denecimig, no new timeline

Novo announced the FDA has not yet completed its review of the BLA for denecimig, a treatment for hemophilia A, and has provided no new timeline for a decision. This extends regulatory uncertainty for the drug's approval, potentially delaying market entry and affecting Novo's pipeline expectations.

Dagens Industri3 days agoUS, DKCredibility 28%View source

Score Breakdown

Mosaic Score5.2
Model confidence0.9
Significance0.5
Source credibility0.3

Intelligence Tags

#fda#pharmaceuticals#regulatory#hemophilia#novo

Entities

country
Source

Related signals

8 found